Yanhui Cui

Dr. Yanhui Cui


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
HZHui Zhang
Hui Zhang
LWLaifa Wang
Laifa Wang
YYYongping Yang
Yongping Yang
CCChuanhai Cai
Chuanhai Cai
XWXueqin Wang
Xueqin Wang
YCYanhui Cui
Yanhui Cui
Currently, the recovery of cognitive function has become an essential part of stroke rehabilitation. DL-3-n-butylphthalide (NBP) is a neuroprotective reagent and has been used in stroke treatment. Clinical studies have confirmed that NBP can achieve better cognitive outcomes in ischemic stroke patients than in healthy controls. In this study, we aimed to investigate the influences of NBP on cognitive function in an ischemic reperfusion (I/R) rat model. Our results showed that NBP profoundly decreased neurological scores, reduced cerebral infarct areas and enhanced cerebral blood flow (CBF). NBP potently alleviated poststroke cognitive impairment (PSCI) including depression-like behavior and learning, memory and social cognition impairments, in I/R rats. NBP distinctly suppressed the activation of microglia and astrocytes and improved neuron viability in the ischemic brain. NBP inhibited the expression of inflammatory cytokines, including interleukin-6 (IL-6), interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), by targeting the nuclear factor kappa B/inducible nitric oxide synthase (NF-κB/iNOS) pathway and decreased cerebral oxidative stress factors, including reactive oxygen species (ROS) and malondialdehyde (MDA), by targeting the kelch like ECH associated protein 1/nuclear factor-erythroid 2 p45-related factor 2 (Keap1/Nrf2) pathway in the ischemic brain. The current study revealed that NBP treatment improved neurological function and ameliorated cognitive impairment in I/R rats, possibly by synergistically suppressing inflammation and oxidative stress.

17 May 2023 in European Journal of Pharmacology
Verified
Journal Article
Closed access
HZHui Zhang
Hui Zhang
LWLaifa Wang
Laifa Wang
BZBi Zhu
Bi Zhu
YYYongping Yang
Yongping Yang
CCChuanhai Cai
Chuanhai Cai
Wenhu ZhouWenhu Zhou
Wenhu Zhou

14 November 2022 in International Immunopharmacology
Verified
Journal Article
Closed access
LWLaifa Wang
Laifa Wang
XWXueqin Wang
Xueqin Wang
LDLing Deng
Ling Deng
HZHui Zhang
Hui Zhang
BHBinsheng He
Binsheng He
YCYanhui Cui
Yanhui Cui

20 July 2021 in Frontiers in Neuroscience
Verified
Journal Article
Open access
YCYanhui Cui
Yanhui Cui
SZShi-Fen Zhou
Shi-Fen Zhou
YLYu Liu
Yu Liu
SWShuang Wang
Shuang Wang
FLFang Li
Fang Li
CLChangqi Li
Changqi Li
Sepsis-associated encephalopathy (SAE) is a risk factor for cognitive and memory dysfunction; however, the mechanism remains unclear. Brain-derived neurotrophic factor (BDNF) was reported to have a positive effect on cognition and emotion regulation, but the study of its precursor, proBDNF, has been limited. This study aimed to elucidate the effects and associated mechanisms of hippocampal proBDNF in a lipopolysaccharide (LPS)-induced SAE mouse model. In this study, we found that the mice exhibited cognitive dysfunction on day 7 after LPS injection. The expression of proBDNF and its receptor, p75NTR, was also increased in the hippocampus, while the levels of BDNF and its receptor, TrkB, were decreased. A co-localization study showed that proBDNF and p75NTR were mainly co-localized with neurons. Furthermore, LPS treatment reduced the expression of NeuN, Nissl bodies, GluR4, NR1, NR2A, and NR2B in the hippocampus of SAE mice. Furthermore, an intrahippocampal or intraperitoneal injection of anti-proBDNF antibody was able to ameliorate LPS-induced cognitive dysfunction and restore the expression of NeuN, Nissl bodies, GluR4, NR1, NR2A, NR2B, and PSD95. These results indicated that treatment with brain delivery by an intrahippocampal and systemic injection of mAb-proBDNF may represent a potential therapeutic strategy for treating patients with SAE.

10 July 2018 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
ZHZhao-lan Hu
Zhao-lan Hu
YCYanhui Cui
Yanhui Cui
XQXiaoqing Qiao
Xiaoqing Qiao
XHXinwen He
Xinwen He
FLFang Li
Fang Li
RDRuchun Dai
Ruchun Dai
MiR-150 regulates maturation and differentiation of T cells but how it functions in multiple sclerosis (MS) is unclear. In miR-150 knockout (KO) mice, we examined the effect of miR-150 deletion on disease severity of experimental autoimmune encephalomyelitis (EAE), an animal model of MS. After deleting miR-150, EAE disease severity was reduced according to clinical score. Histological staining and MBP immunofluorescence staining revealed that miR-150 deletion limited the extent of inflammatory demyelination and axonal damage in the spinal cord. Flow cytometry showed that CD3+, CD4+, and CD8+ T cells were increased in WT-EAE mice, but miR-150 deletion significantly reversed EAE-mediated up-regulation of CD3+, CD4+, and CD8+ T cells and down-regulation of CD19+ B cells. In addition, miR-150 deletion reduced the mRNA expression of IL-1β, IL-6, IL-17, and TNF-α in spleen and spinal cord after EAE induction. Thus, miR-150 deletion reduces EAE severity and demyelination, probably through inhibiting the activated immune response and the inflammation in the central nervous system.

1 March 2023 in Epigenomics
Verified
Journal Article
Closed access
XWXueqin Wang
Xueqin Wang
JSJinquan Shen
Jinquan Shen
LWLaifa Wang
Laifa Wang
LDLing Deng
Ling Deng
HBHao Bo
Hao Bo
YCYanhui Cui
Yanhui Cui
Background: LINC00518 acts as an oncogene in several cancers, but its function in head and neck squamous cell carcinoma (HNSCC) remains unclear. Materials & methods: The expression and methylation ...